Anxiety Zone Forums | Login | Register | Announcements | Introduce Yourself | The Lounge | Inspiration Place | Generalized Anxiety Disorder (GAD) | Hypochondria (Health Anxiety) | Panic Disorder and Agoraphobia | Clinical Depression | Specific Phobias | Post-Traumatic Stress Disorder (PTSD) | Social Anxiety Disorder | Obsessive-Compulsive Disorder (OCD) | Other Mental Health Issues | Sleep Disorders | Fibromyalgia & Chronic Fatigue Syndrome (CFS) | Digestive Disorders | Medications and Therapy | Addiction and Recovery | Relationship Issues | The Anxiety Zone Arcade | Conditions Index | Drug Index | Glossary | Symptoms | Therapies | Latest Health News | Member Articles | Member Blogs | Member Gallery | Chat Rooms (Reg. required.) | Search | Community Guidelines

Support Forums And Chats For Generalized Anxiety Disorder (GAD), Hypochondria, Panic Disorder, Clinical Depression, Specific Phobias, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder and Obsessive-Compulsive Disorder (OCD).
- Click on the banner above to visit the Anxiety Zone forums -

Reboxetine

Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesilate (i.e. methanesulfonate) salt is sold under tradenames including Edronax®, Norebox®, Prolift®, Solvex® or Vestra®. Chemically it is (±)-(2R*)-2-[(?R*)-?-(o-ethoxyphenoxy)benzyl]morpholine.

Unlike most antidepressants on the market, Reboxetine is a noradrenaline reuptake inhibitors (NARI); it does not inhibit the reuptake of serotonin, though it can be safely combined with an SSRI. Reboxetine is currently marketed by Pharmacia & Upjohn.

By mid-2001, reboxetine was licensed worldwide in over 50 countries, including Italy, Germany and the UK. In May 2001, however, the FDA declined Pharmacia's license application for the American market. As such it is yet to be available in the US.

Common side effects of reboxetine include: dry mouth, constipation, headache, drowsiness, dizziness, excessive sweating and insomnia.

Reboxetine has a relatively short elimination half life of 12.5 hours and therefore is often given twice daily.

The information above is not intended for and should not be used as a substitute for the diagnosis and/or treatment by a licensed, qualified, health-care professional. This article is licensed under the GNU Free Documentation License. It incorporates material originating from the Wikipedia article "Reboxetine".

Copyright © 2009 Anxiety Zone - Anxiety Disorders Forum. All Rights Reserved.